Skip to main content

COVID-19 Topic Center

Atopic Dermatitis News

News
Depression, anxiety, and sleep difficulties are common in US patients with moderate-to-severe atopic dermatitis and are associated with work impairment and reductions in health status and health-related quality of life, according to a study published in Advances in Therapy.  “The findings of the…
News
More than three-quarters of adults with atopic dermatitis who initiated dupilumab remained on the treatment 12 months later, according to real-world findings published in the journal Annals of Allergy, Asthma & Immunology.  “Persistence with dupilumab therapy was high,” researchers wrote, “and…
News
Cumulative doses of phototherapy and related costs varied greatly among seven skin diseases in a single-center analysis of 561 patients published online ahead of print in the journal Photodermatology, Photoimmunology & Photomedicine.  Noting that current recommendations do not adequately…
News
A 35-year-old man with severe erythrodermic atopic dermatitis experienced clearance of his disease after 4 months of adding rescue tofacitinib to dupilumab therapy, according to a study published in JAAD Case Reports.  In their report, Danielle M Peterson, MD, and Matthew D. Vesely, MD, of the…
News
More than 97% of surveyed councilors and associates from the International Eczema Council agreed that therapeutic patient education should play an important role in atopic dermatitis management, according to a study published in JAAD International.  “Publications have shown the positive effect of…
News
According to study findings published online in the Journal of the American Academy of Dermatology, Patient-Reported Outcomes Measurement Information System Global Health (PGH) scores had sufficient validity and reliability to assess health-related quality of life in atopic dermatitis (AD).   “PGH…
News
For the treatment of moderate-to-severe atopic dermatitis, biologics with the most robust efficacy and safety evidence are dupilumab, baricitinib, abrocitinib, and delgocitinib, according to a systematic review published online ahead of print in the journal Dermatology.   “As many patients are…
News
Prior authorizations are costly to dermatology practices, with one institution dedicating 170 staff hours to prior authorizations, amounting to $5822.98 in costs, over a 30-day period. Researchers published their findings in JAMA Dermatology.   “Based on the estimated 6000 visits per year for US…
News
An analysis of the characteristics of 308 adults with moderate-to-severe atopic dermatitis starting or switching systematic therapy provides a real-world picture of the substantial burden of the disease, observed researchers in the Journal of Dermatological Treatment.   Their study summarized the…
News
More than 40% of US patients with atopic dermatitis or their caregivers say they spend $1000 or more out of pocket annually to manage the condition, according to a study published online in Dermatitis.  “Using a survey-based approach to highlight the perspective of atopic dermatitis patients and…
Back to Top